Document
IPR2023-00724, No. 1038 Exhibit - Seino 2008 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1038 Exhibit - Seino 2008 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1043 Exhibit - US20040102486 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1043 Exhibit - US20040102486 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2487 Exhibit - EX2487 US Patent No 8,129,343 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2487 Exhibit - EX2487 US Patent No 8,129,343 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2474 Exhibit - EX2474 US Food Drug Administration, DrugsFDA, Mounjaro (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2474 Exhibit - EX2474 US Food Drug Administration, DrugsFDA, Mounjaro (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2505 Exhibit - EX2505 Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 Feb 3, 2021 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2505 Exhibit - EX2505 Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 Feb 3, 2021 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2390 Exhibit - EX2390 Usherwood, T, Encouraging adherence to long term medication, Aust Prescr, 2017 Aug 404147 150 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2390 Exhibit - EX2390 Usherwood, T, Encouraging adherence to long term medication, Aust Prescr, 2017 Aug 404147 150 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2430 Exhibit - EX2430 Oseni® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2430 Exhibit - EX2430 Oseni® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2446 Exhibit - EX2446 Trulicity® Prescribing Information rev June 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2446 Exhibit - EX2446 Trulicity® Prescribing Information rev June 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1116 Exhibit - Exhibit 1116 Mounjaro label (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1116 Exhibit - Exhibit 1116 Mounjaro label (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2462 Exhibit - EX2462 US Food Drug Administration, DrugsFDA, Qtern (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2462 Exhibit - EX2462 US Food Drug Administration, DrugsFDA, Qtern (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2524 Exhibit - EX2524 Eli Lilly Co, 2019 Financial Report (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2524 Exhibit - EX2524 Eli Lilly Co, 2019 Financial Report (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1142 Exhibit - Exhibit 1142 Radbill (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1142 Exhibit - Exhibit 1142 Radbill (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2551 Exhibit - EX2551 Opening Expert Report of William J Jusko, PhD Regarding Inva lidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038
Cite Document
IPR2023-00724, No. 2551 Exhibit - EX2551 Opening Expert Report of William J Jusko, PhD Regarding Inva lidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038
+ More Snippets
Document
IPR2023-00724, No. 2653 Exhibit - EX2653 July 8, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft p...
Cite Document
IPR2023-00724, No. 2653 Exhibit - EX2653 July 8, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft proposed motion
+ More Snippets
Document
IPR2023-00724, No. 2084 Exhibit - EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes SUSTAIN 7 a randomized, open label, phase 3b trial,” La...
Cite Document
IPR2023-00724, No. 2084 Exhibit - EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes SUSTAIN 7 a randomized, open label, phase 3b trial,” Lancet Dia
+ More Snippets